Vivia Biotech

Vivia Biotech is a Spanish CRO founded in 2019, offering a specialized suite of ex vivo assay services to support drug development in hematologic malignancies, solid tumors, and autoimmune diseases. Its core value proposition is the generation of highly predictive, clinically relevant data by testing compounds directly on patient-derived samples within physiologically relevant microenvironments. The company provides end-to-end project management, from assay design and execution to data analysis and reporting, targeting pharmaceutical and biotech clients. With a claimed 15+ years of underlying platform experience, Vivia Biotech positions itself as a partner for translational research and precision medicine.

Proprietary ex vivo assay platforms using patient-derived samples (blood, bone marrow, tumor tissue) to preserve the native hematopoietic or tumor microenvironment. Includes 3D solid tumor cultures, integrated molecular biology (genomic, transcriptomic, epigenetic profiling), and bioinformatic analysis for multimodal data integration.

Vivia Biotech competes in the preclinical CRO market against large, full-service players (e.g., LabCorp, Charles River) and numerous niche specialists offering organoid, PDX, or other ex vivo services. Its differentiation is the specific focus on functional drug response in a preserved native microenvironment, combined with integrated omics, for translational decision-making.